Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Pathol Oncol Res ; 26(2): 727-734, 2020 Apr.
Article in English | MEDLINE | ID: mdl-30734151

ABSTRACT

BPAP is a potent enhancer substance with catecholaminergic and serotoninergic activity in the brain. It was discovered that it is also effective against certain types of experimental cancers, showing the most promising results in case of lung cancer. That is why we tested its efficacy in two different doses in a newly developed EGFR wild type mouse lung adenocarcinoma xenograft model. Experiments were conducted on FVB/N and SCID mouse strains treated with low and high dose of BPAP. Body weight, survival, and tumor volumes were recorded. Furthermore, the activity of major signaling pathways of NSCLC such as MAPK and Akt/mTOR as well as cell cycle regulation were determined. Significant inhibition of tumor growth was exerted by both doses, but the mechanism of action was different. High dose directly inhibited, whereas low dose activated the main signaling pathways. Exposure to low dose BPAP resulted in elevated activity of the mTOR pathway together with p16INK-induced cell cycle arrest, a typical feature of geroconversion, a senescent state characterized by loss of cell proliferation. Finally the events culminated in cell cycle inhibition point in case of both doses mirrored by the decrease of cyclin D1, CDK4 and PCNA. In addition, BPAP treatment had a beneficial effect on bodyweight suggesting that the compound at least in part is able to compensate the cancer-related wasting. In view of the low toxicity and confirmed antitumor effect of BPAP against experimental lung adenocarcinoma, this novel compound deserves further attention.


Subject(s)
Adenocarcinoma of Lung/pathology , Benzofurans/pharmacology , Lung Neoplasms/pathology , Animals , Cell Cycle Checkpoints/drug effects , Humans , Mice , Signal Transduction/drug effects , Xenograft Model Antitumor Assays
2.
Behav Brain Res ; 378: 112290, 2020 01 27.
Article in English | MEDLINE | ID: mdl-31610214

ABSTRACT

Pharmaceutically available enhancer selegiline/(-)-deprenyl (DEP) in the clinically used dose shows antidepressant effect, but nothing is known about this effect in enhancer dose, and its effect on co-morbid anxiety. Moreover, data about the antidepressant/antianxiety effects of the serotonin-influencing enhancer, (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) are also missing. The aim of the present paper is to establish the role of enhancer regulation in anxiety and follow the changes in the phosphorylation of glutamate subunits in prefrontal cortex as well as stress-related organ and hormonal changes as possible background mechanism. The effect of 3-week-treatment of rats with specific (0.001 mg/kg for DEP, 0.0001 mg/kg for BPAP) and non-specific (0.1 mg/kg for DEP, 0.05 mg/kg for BPAP) enhancer doses were evaluated on anxiety-like behavior in the elevated plus maze (EPM) and open-field (OF) tests. Phosphorylated glutamatergic GluR1 and GluN2B subunits were analyzed by Western blot. Changes in the stress-regulatory system were evaluated by measuring the organ weights and blood corticosterone concentrations. Non-specific enhancer doses had a tendency for anxiolysis on EPM, while only 0.1 mg/kg DEP elevated motility in OF. Specific enhancer doses significantly increased the expression of both glutamatergic receptor subunits; non-specific doses elevated only pGluR1. Treatments had no effects on stress-like organ weights; however, the specific enhancer doses significantly reduced the dark phase resting corticosterone levels. The study proved the enhancer-sensitivity of the glutamatergic transmitter system and suggested enhancer-induced stabilization of stress-hormone levels without major impact on non-stimulated anxiety-like behavior.


Subject(s)
Anxiety/drug therapy , Behavior, Animal/drug effects , Benzofurans/pharmacology , Neurotransmitter Agents/pharmacology , Receptors, AMPA/drug effects , Receptors, N-Methyl-D-Aspartate/drug effects , Selegiline/pharmacology , Stress, Psychological/drug therapy , Animals , Anxiety/metabolism , Benzofurans/administration & dosage , Corticosterone/blood , Disease Models, Animal , Drug Synergism , Glutamic Acid/drug effects , Glutamic Acid/metabolism , Male , Maze Learning/drug effects , Neurotransmitter Agents/administration & dosage , Rats , Rats, Wistar , Selegiline/administration & dosage , Stress, Psychological/metabolism
3.
Exp Biol Med (Maywood) ; 243(12): 1014-1023, 2018 08.
Article in English | MEDLINE | ID: mdl-30111166

ABSTRACT

MiR-206 is a remarkable miRNA because it functions as a suppressor miRNA in rhabdomyosarcoma while at the same time, as previously showed, it can act as an oncomiRNA in SMARCB1 immunonegative soft tissue sarcomas. The aim of this study was to investigate the effect of miR-206 on its several target genes in various human tumorous and normal cell lines. In the current work, we created miR-206-overexpressing cell lines (HT-1080, Caco2, iASC, and SS-iASC) using permanent transfection. mRNA expression of the target genes of miR-206 (SMARCB1, ACTL6A, CCND1, POLA1, NOTCH3, MET, and G6PD) and SMARCB1 protein expression were examined with quantitative real-time polymerase chain reaction, immunoblotting, immunocytochemistry, and flow cytometry. MiRNA inhibition was used to validate our results. We found a diverse silencing effect of miR-206 on its target genes. While an overall tendency of downregulation was noted, expression profiles of individual cell lines showed large variability. Only CCND1 and MET were consistently downregulated. MiR-206 had an antiproliferative effect on a normal human fibroblast cell line. A strong silencing effect of SMARCB1 in miR-206 transfected SS-iASC was most likely caused by the synergic influence of the SS18-SSX1 fusion protein and miR-206. In the same cell line, a moderate decrease of SMARCB1 protein expression could be observed with immunocytochemistry and flow cytometry. In the most comprehensive analysis of miR-206 effects so far, a modest but significant downregulation of miR-206 targets on the mRNA level was confirmed across all cell lines. However, the variability of the effect shows that the action of this miRNA is largely cell context-dependent. Our results also support the conception that the oncomiR effect of miR-206 on SMARCB1 plays an important but not exclusive role in SMARCB1 immunonegative soft tissue sarcomas so it can be considered important in planning the targeted therapy of these tumors in the future. Impact statement Mir-206 is a very unique microRNA because it can act as a suppressor miRNA or as an oncomiRNA depending on the tumor tissue. In SMARCB1 negative soft tissue sarcomas miR-206 is overexpressed, so thus in epithelioid and synovial sarcomas it functions as an oncomiRNA. MiR-206 has diverse silencing effects on its target genes. We found that the action of miR-206 is largely cell context dependent. The oncomiR role of miR-206 is crucial but not exclusive in SMARCB1 negative soft tissue sarcomas and miR-206 has an antiproliferative effect on a normal human fibroblast cell line. Expressions of miR-206 targets observed in tumors can only be reproduced in the corresponding tumorous cell lines. This is the first study which examined the permanent effect of miR-206 on its target genes in normal, tumor, and genetically engineered cell lines.


Subject(s)
MicroRNAs/genetics , MicroRNAs/metabolism , Rhabdomyosarcoma/genetics , Transfection , Caco-2 Cells , Cell Line, Tumor , Down-Regulation , Epigenesis, Genetic , Fibroblasts/metabolism , Gene Expression Profiling , Gene Silencing , Humans , Immunohistochemistry , Rhabdomyosarcoma/drug therapy , SMARCB1 Protein/genetics , SMARCB1 Protein/metabolism , Sarcoma/drug therapy , Sarcoma/genetics , Signal Transduction
4.
Fitoterapia ; 127: 413-419, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29653155

ABSTRACT

While analyzing the fruit composition of nine European Cirsium species representing three sections (i.e., Cephalonoplos, Chamaeleon and Eriolepis), four lignans, three neolignans and three sesquineolignans were determined and used as chemotaxonomic markers. Among them, desmethyl balanophonin and desmethyl picrasmalignan were determined for the first time in the plant kingdom, as the main metabolites of the Chamaeleon section. Prebalanophonin and prepicrasmalignan, identified so far exclusively in C. eriophorum, were also confirmed in C. boujartii and C. vulgare, highlighting the chemotaxonomic significance of these compounds in the Eriolepis section. The antiproliferative assay of the compounds isolated from their optimum sources, confirmed a dose-dependent inhibitory effect of the structures bearing the 4',7-epoxy moiety (balanophonin, picrasmalignan, desmethyl balanophonin, desmethyl picrasmalignan) against SW480 colon cancer cells, while those bearing the 4',7-dihydroxy motif (prebalanophonin, prepicrasmalignan) were inactive.


Subject(s)
Antineoplastic Agents, Phytogenic/isolation & purification , Cirsium/chemistry , Fruit/chemistry , Lignans/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Cell Line, Tumor , Humans , Lignans/pharmacology , Molecular Structure , Phytochemicals/analysis
5.
BMC Cancer ; 18(1): 157, 2018 02 07.
Article in English | MEDLINE | ID: mdl-29415661

ABSTRACT

BACKGROUND: Diethylnitrosamine is a well known carcinogen that induces cancers of various organs in mice and rats. Using FVB/N mouse strain, here we show that diethylnitrosamine induces primarily lung adenocarcinomas with modest tumor development in the liver, offering a new model to study chemical carcinogenesis in the lung. METHODS: Animals were exposed to a single high dose of diethylnitrosamine, and more than 70% of the mice developed lung cancer. To obtain a new transplantable tumor line, pieces of primary tumors were inoculated and maintained subcutaneously in the same mouse strain. We used immunohistochemistry to characterize the tumor for main lung adenocarcinoma markers. We searched for mutations in KRAS exon 2 and EGFR exon 19, 21 with Sanger sequencing. We also compared the normal lung tissue with the diethylnitrosamine induced primary adenocarcinoma, and with the subcutaneously maintained adenocarcinoma using Western blot technique for main cell cycle markers and to identify the main pathways. RESULTS: Primary and subcutaneous tumors express cytokeratin-7 and thyroid transcription factor-1, markers characteristic to lung adenocarcinoma. In addition, no mutations were found in the hot spot regions of KRAS and EGFR genes. We found high mTOR activation, but the level of p-Akt Ser473 and p-Akt Thr308 decreased in the tumorous samples. CONCLUSIONS: We established a new lung adenocarcinoma model using FVB/N mouse strain and diethylnitrosamine. We believe that this new model system would be highly useful in lung cancer research.


Subject(s)
Adenocarcinoma/pathology , Disease Models, Animal , Lung Neoplasms/pathology , Lung/pathology , Adenocarcinoma/chemically induced , Adenocarcinoma/genetics , Animals , Base Sequence , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Diethylnitrosamine , ErbB Receptors/genetics , Female , Humans , Keratin-7/metabolism , Lung/metabolism , Lung Neoplasms/chemically induced , Lung Neoplasms/genetics , Male , Mice , Mutation , Proto-Oncogene Proteins p21(ras)/genetics , Thyroid Nuclear Factor 1/metabolism
6.
Fitoterapia ; 100: 19-26, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25447161

ABSTRACT

The molecular constituents of Cirsium brachycephalum fruits were identified, quantified and isolated for the first time. The lignan glycoside tracheloside was the main compound, which was transformed quantitatively into its aglycone trachelogenin by endogenous enzymatic treatment of the fruit. Following this transformation by high performance liquid chromatography (HPLC) hyphenated with UV and mass spectrometry (MS) detections on a quantitative basis, the enzyme-hydrolyzed fruit was found to be the richest raw material containing trachelogenin (17.2mg/g) reported to date. Thus, the enzyme-hydrolyzed fruit was used to isolate trachelogenin using preparative HPLC in order to (1) unambiguously confirm its identity by gas chromatography-MS, nuclear magnetic resonance spectroscopy and optical rotation, and (2) investigate its in vitro antiproliferative activities against the SW480 colon adenocarcinoma cell line. Trachelogenin significantly affected the phosphorylation of key proteins such as ß-Catenin, c-Myc and GSK3 in the ß-Catenin signaling pathway in a concentration-dependent manner. These changes account for the antiproliferative effects of trachelogenin.


Subject(s)
4-Butyrolactone/analogs & derivatives , Antineoplastic Agents, Phytogenic/pharmacology , Cirsium/chemistry , Wnt Signaling Pathway/drug effects , 4-Butyrolactone/pharmacology , Adenocarcinoma/pathology , Cell Line, Tumor , Colonic Neoplasms/pathology , Fruit/chemistry , Glycogen Synthase Kinase 3/metabolism , Humans , Lignans/pharmacology , Molecular Structure , Proto-Oncogene Proteins c-myc/metabolism , beta Catenin/metabolism
7.
Nat Prod Res ; 28(10): 732-9, 2014.
Article in English | MEDLINE | ID: mdl-24483775

ABSTRACT

Dibenzylbutyrolactone-type lignan glycosides (tracheloside and carthamoside), their aglycones (trachelogenin and carthamogenin) and feruloyl-serotonin isomers were determined in the fruits of Leuzea carthamoides by using LC-UV, LC-MS/MS and GC-MS techniques. The composition of the embryo and wall parts of the fruits was analysed before and after their hydrolysis. As a result of these studies, fruit part-specific accumulation of lignan glycosides and feruloyl-serotonins were confirmed, demonstrating that the embryo contains a high amount of lignan glycosides (tracheloside 32.9 mg/g, carthamoside 45.3 mg/g), while the wall part of the fruit accumulates feruloyl-serotonins (63.0 mg/g). Enzymatic hydrolysis of the embryo resulted in the quantitative transformation of lignan glycosides into their corresponding aglycones, allowing selective isolation of trachelogenin and carthamogenin. These aglycones were subjected to an antiproliferative study against the SW480 colon adenocarcinoma cell line. In this test, moderate activity of carthamogenin and a significant effect of trachelogenin were demonstrated in a concentration range of 22-185 µM.


Subject(s)
Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Fruit/chemistry , Glycosides/isolation & purification , Glycosides/pharmacology , Leuzea/chemistry , Lignans/isolation & purification , Lignans/pharmacology , 4-Butyrolactone/analogs & derivatives , 4-Butyrolactone/analysis , Antineoplastic Agents, Phytogenic/chemistry , Drug Screening Assays, Antitumor , Gas Chromatography-Mass Spectrometry , Glycosides/chemistry , Humans , Hungary , Hydrolysis , Lignans/analysis , Lignans/chemistry , Molecular Structure
SELECTION OF CITATIONS
SEARCH DETAIL
...